LOC339975: A Potential Drug Target and Cancer Biomarker (G339975)
LOC339975: A Potential Drug Target and Cancer Biomarker
LOC339975 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LOC3399 family, which is characterized by the presence of a single transmembrane domain and a unique N-terminus that is rich in amino acids.
The primary function of LOC339975 is not well understood, but it is believed to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival. LOC339975 has been shown to interact with several other proteins, including the transcription factor NF-kappa-B and the protein PDGF-B.
One of the most promising aspects of LOC339975 is its potential as a drug target. LOC339975 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, LOC339975 has been shown to be involved in the regulation of cancer cell survival and angiogenesis.
In addition to its potential as a drug target, LOC339975 has also been shown to be a potential biomarker for various types of cancer. The expression of LOC339975 has been shown to be associated with the development and progression of cancer, and high levels of LOC339975 have been shown to be associated with poor prognosis in cancer patients.
Overall, LOC339975 is a protein that is of great interest to researchers as a potential drug target and biomarker for various types of cancer. Further studies are needed to fully understand its function and its potential as a therapeutic agent.
Protein Name: Uncharacterized LOC339975
The "LOC339975 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC339975 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC340090 | LOC340184 | LOC340512 | LOC343052 | LOC344967 | LOC349160 | LOC374443 | LOC375196 | LOC387720 | LOC388242 | LOC388780 | LOC389199 | LOC389473 | LOC389765 | LOC389831 | LOC389834 | LOC389895 | LOC389906 | LOC390282 | LOC390705 | LOC391092 | LOC391343 | LOC391813 | LOC392180 | LOC392196 | LOC392232 | LOC399783 | LOC399900 | LOC400347 | LOC400464 | LOC400499 | LOC400541 | LOC400576 | LOC400622 | LOC400627 | LOC400682 | LOC400692 | LOC400706 | LOC400707 | LOC400768 | LOC400940 | LOC401021 | LOC401052 | LOC401127 | LOC401261 | LOC401312 | LOC401324 | LOC401357 | LOC401410 | LOC401478 | LOC401480 | LOC401557 | LOC401589 | LOC401703 | LOC401913 | LOC402221 | LOC403312 | LOC407835 | LOC414300 | LOC439933 | LOC440157 | LOC440300 | LOC440311 | LOC440313 | LOC440700 | LOC440864 | LOC440895 | LOC440910 | LOC440982 | LOC441052 | LOC441081 | LOC441087 | LOC441179 | LOC441228 | LOC441239 | LOC441455 | LOC441666 | LOC441722 | LOC441956 | LOC442028 | LOC442497 | LOC497256 | LOC541473 | LOC550113 | LOC553139 | LOC554206 | LOC574080 | LOC606724 | LOC613266 | LOC642131 | LOC642361 | LOC642422 | LOC642502 | LOC642590 | LOC642677 | LOC642730 | LOC642846 | LOC642947 | LOC643201 | LOC643339
